Generic-Reglan Suits Doomed By Catch-22, 6th Circ. Says
Law360, Los Angeles (December 2, 2013, 6:13 PM EST) -- A Sixth Circuit panel on Monday refused to revive seven lawsuits alleging a generic version of digestion medication Reglan caused users to develop a serious neurological condition, ruling the plaintiffs were caught in a catch-22 preventing them from bringing claims against generic or brand-name manufacturers.
Writing for the panel U.S. Circuit Judge Ronald Lee Gilman, upheld a lower court's decision dismissing the cases on the grounds that the plaintiffs had taken metoclopramide, the generic name for Reglan, and brand-name manufacturers couldn’t be held liable under the Tennessee Products Liability Act for injuries from products they didn’t make. The lower court also...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!